JP2020530272A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530272A5 JP2020530272A5 JP2019572456A JP2019572456A JP2020530272A5 JP 2020530272 A5 JP2020530272 A5 JP 2020530272A5 JP 2019572456 A JP2019572456 A JP 2019572456A JP 2019572456 A JP2019572456 A JP 2019572456A JP 2020530272 A5 JP2020530272 A5 JP 2020530272A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1710835.8 | 2017-07-05 | ||
| GBGB1710835.8A GB201710835D0 (en) | 2017-07-05 | 2017-07-05 | ROR1 Antibodies |
| PCT/GB2018/051914 WO2019008377A1 (en) | 2017-07-05 | 2018-07-05 | ANTIBODY ROR1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530272A JP2020530272A (ja) | 2020-10-22 |
| JP2020530272A5 true JP2020530272A5 (enExample) | 2021-08-12 |
| JP7242573B2 JP7242573B2 (ja) | 2023-03-20 |
Family
ID=59592560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572456A Active JP7242573B2 (ja) | 2017-07-05 | 2018-07-05 | Ｒｏｒ１抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11466083B2 (enExample) |
| EP (1) | EP3649152B1 (enExample) |
| JP (1) | JP7242573B2 (enExample) |
| CN (1) | CN110891973B (enExample) |
| AU (1) | AU2018297630B2 (enExample) |
| CA (1) | CA3068196A1 (enExample) |
| DK (1) | DK3649152T3 (enExample) |
| ES (1) | ES3048696T3 (enExample) |
| GB (1) | GB201710835D0 (enExample) |
| MX (1) | MX2019015348A (enExample) |
| WO (1) | WO2019008377A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201710835D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| GB201710836D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
| US20230416942A1 (en) * | 2020-08-21 | 2023-12-28 | Yale University | Nanobody Compositions and Methods of Use of the Same |
| TWI907489B (zh) * | 2020-08-24 | 2025-12-11 | 香港商岸邁生物科技（香港）有限公司 | 抗ｒｏｒ１抗體及相關雙特異性結合蛋白 |
| CN116323946A (zh) * | 2020-09-03 | 2023-06-23 | 和铂医药(上海)有限责任公司 | 靶向ror1的抗体或其抗原结合片段及制备方法和应用 |
| EP4247848A4 (en) * | 2020-11-23 | 2025-10-01 | Scout Bio Inc | ANTIGEN-BINDING MOLECULES AND THEIR USES |
| WO2022182562A1 (en) * | 2021-02-23 | 2022-09-01 | BioLegend, Inc. | ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN S1 AGENTS AND COMPOSITIONS |
| CA3172530A1 (en) | 2021-02-25 | 2022-09-01 | Spencer PARK | Ror1 targeting chimeric antigen receptor |
| CN115151572B (zh) * | 2021-07-23 | 2023-09-15 | 浙江时迈药业有限公司 | 针对ror1的抗体及其用途 |
| CN113956359B (zh) * | 2021-10-29 | 2022-09-16 | 叶鑫淼 | 一种抗体及其在抗肿瘤中的应用 |
| TW202330619A (zh) * | 2021-12-28 | 2023-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｒｏｒ１抗體和抗ｒｏｒ１抗體藥物偶聯物及其醫藥用途 |
| CN119604529A (zh) * | 2022-07-11 | 2025-03-11 | 翰森生物有限责任公司 | 抗体、其抗原结合片段及其药物用途 |
| CN115724973B (zh) * | 2022-09-26 | 2023-07-11 | 普健生物（武汉）科技有限公司 | 抗人ror1高亲和力兔单克隆抗体及其应用 |
| CN116903740B (zh) * | 2023-04-21 | 2024-04-30 | 星奕昂(上海)生物科技有限公司 | 靶向ror1的抗体及其应用 |
| WO2025044937A1 (zh) * | 2023-08-31 | 2025-03-06 | 正大天晴药业集团股份有限公司 | 靶向受体酪氨酸激酶样孤儿受体1的抗体及其应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4948174B2 (ja) | 2003-10-16 | 2012-06-06 | マイクロメット アクツィエン ゲゼルシャフト | 多重特異的脱免疫ｃｄ３−結合物質 |
| WO2007146957A2 (en) | 2006-06-13 | 2007-12-21 | Irm Llc | Ror1 as a therapeutic target for lung cancer |
| EP2421899B1 (en) * | 2009-04-23 | 2016-06-08 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-human ror1 antibodies |
| EP2496605A1 (en) | 2009-11-02 | 2012-09-12 | Oxford Biotherapeutics Ltd. | Ror1 as therapeutic and diagnostic target |
| CN102712695B (zh) | 2009-12-18 | 2015-01-21 | 堪瑟拉公司 | 能够诱导细胞死亡的ror1生物抑制剂 |
| WO2012045085A1 (en) | 2010-10-01 | 2012-04-05 | Oxford Biotherapeutics Ltd. | Anti-rori antibodies |
| WO2012075158A1 (en) | 2010-12-01 | 2012-06-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric rabbit/human ror1 antibodies |
| GB201020995D0 (en) * | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| EP3252076B1 (en) | 2011-01-14 | 2019-09-04 | The Regents Of The University Of California | Diagnostic use of antibodies against ror-1 protein |
| KR102264290B1 (ko) | 2012-08-20 | 2021-06-10 | 프레드 헛친슨 켄서 리서치 센터 | 세포 면역요법을 위한 방법 및 조성물 |
| US9758591B2 (en) | 2012-08-24 | 2017-09-12 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis |
| EP2789630A1 (en) * | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| TWI742423B (zh) | 2014-05-29 | 2021-10-11 | 美商宏觀基因股份有限公司 | 特異性結合多種癌症抗原的三特異性結合分子和其使用方法 |
| KR102048855B1 (ko) * | 2014-07-29 | 2019-11-26 | 셀렉티스 | 암 면역요법을 위한 ror1(ntrkr1) 특이적 키메라 항원 수용체 |
| CA2956482A1 (en) | 2014-07-31 | 2016-02-04 | Cellectis | Ror1 specific multi-chain chimeric antigen receptor |
| AU2015313268B2 (en) | 2014-09-08 | 2018-12-20 | National Cancer Center | Cancer-cell-specific antibody, anticancer agent, and cancer testing method |
| US20170306044A1 (en) | 2014-10-09 | 2017-10-26 | Engmab Ag | Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer |
| AU2015329965A1 (en) | 2014-10-09 | 2017-04-27 | Engmab Sàrl | Bispecific antibodies against CD3epsilon and ROR1 |
| WO2016094873A2 (en) | 2014-12-12 | 2016-06-16 | Emergent Product Development Seattle, Llc | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods |
| AU2016206457B2 (en) | 2015-01-16 | 2021-11-11 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ROR1 |
| KR102493943B1 (ko) | 2015-02-02 | 2023-01-31 | 칸세라 아베 | 포유류 티로신 키나제 ROR1 활성의 저해제로서 유용한 2-페닐-3H-이미다조[4,5-b]피리딘 유도체 |
| EP3297671A4 (en) * | 2015-05-18 | 2019-02-06 | Eureka Therapeutics, Inc. | ANTI-ROR1 ANTIBODY |
| US20180147271A1 (en) | 2015-05-18 | 2018-05-31 | Bluebird Bio, Inc. | Anti-ror1 chimeric antigen receptors |
| HK1254836A1 (zh) | 2015-10-30 | 2019-07-26 | Nbe-Therapeutics Ag | 抗-ror1抗体 |
| MX2018008926A (es) | 2016-01-20 | 2019-01-10 | Scripps Research Inst | Composiciones de anticuerpo contra ror1 y métodos relacionados. |
| TW201734049A (zh) | 2016-01-22 | 2017-10-01 | 健生生物科技公司 | 抗－ｒｏｒ１抗體、ｒｏｒ１ ｘ ｃｄ３雙特異性抗體及使用其之方法 |
| UY37127A (es) | 2016-02-17 | 2017-08-31 | Macrogenics Inc | Moléculas de unión a ror1, y métodos de uso de las mismas |
| WO2017156479A1 (en) | 2016-03-11 | 2017-09-14 | Bluebird Bio, Inc. | Ror1 chimeric antigen receptors |
| ES2899113T3 (es) | 2016-07-11 | 2022-03-10 | Kancera Ab | Derivados de 2-fenilimidazo[4,5-b]piridin-7-amina útiles como inhibidores de la actividad tirosina quinasa ROR1 de mamíferos |
| US20200338210A1 (en) | 2016-12-22 | 2020-10-29 | Ardeagen Corporation | Anti-ror1 antibody and conjugates thereof |
| CA3064743A1 (en) | 2017-05-23 | 2018-11-29 | Dragonfly Therapeutics, Inc. | A protein binding nkg2d, cd16 and ror1 or ror2 |
| AU2018289581C1 (en) | 2017-06-23 | 2025-01-30 | VelosBio Inc. | ROR1 antibody immunoconjugates |
| US11518815B2 (en) | 2017-06-25 | 2022-12-06 | Systimmune, Inc. | Anti-ROR1 antibodies and methods of making and using thereof |
| GB201710835D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| GB201710838D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| GB201710836D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| US20210139579A1 (en) | 2017-07-20 | 2021-05-13 | Nbe-Therapeutics Ag | Multispecific antibody product that binds to different ror1 epitopes |
| EP3665193A1 (en) | 2017-08-07 | 2020-06-17 | NBE Therapeutics AG | Anthracycline-based antibody drug conjugates having high in vivo tolerability |
| CN117756946A (zh) | 2017-11-03 | 2024-03-26 | 莱蒂恩技术公司 | 用于用抗ror1免疫治疗来治疗癌症的组合物和方法 |
| GB201721802D0 (en) | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
| WO2019225777A1 (ko) | 2018-05-23 | 2019-11-28 | 에이비엘바이오 주식회사 | 항-ror1 항체 및 그 용도 |
-
2017
- 2017-07-05 GB GBGB1710835.8A patent/GB201710835D0/en not_active Ceased
-
2018
- 2018-07-05 CA CA3068196A patent/CA3068196A1/en active Pending
- 2018-07-05 JP JP2019572456A patent/JP7242573B2/ja active Active
- 2018-07-05 WO PCT/GB2018/051914 patent/WO2019008377A1/en not_active Ceased
- 2018-07-05 CN CN201880045361.4A patent/CN110891973B/zh active Active
- 2018-07-05 MX MX2019015348A patent/MX2019015348A/es unknown
- 2018-07-05 DK DK18742575.6T patent/DK3649152T3/da active
- 2018-07-05 US US16/628,512 patent/US11466083B2/en active Active
- 2018-07-05 AU AU2018297630A patent/AU2018297630B2/en active Active
- 2018-07-05 EP EP18742575.6A patent/EP3649152B1/en active Active
- 2018-07-05 ES ES18742575T patent/ES3048696T3/es active Active
-
2022
- 2022-07-21 US US17/869,872 patent/US20230220073A1/en not_active Abandoned
-
2024
- 2024-08-26 US US18/815,603 patent/US20250066472A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530272A5 (enExample) | ||
| JP2020529839A5 (enExample) | ||
| RU2504551C2 (ru) | Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста | |
| IL276695A (en) | Antibodies, pharmaceutical compositions and uses thereof | |
| RU2018124602A (ru) | Новые анти-pd-l1 антитела | |
| JP2020529838A5 (enExample) | ||
| JP2020534830A5 (enExample) | ||
| RU2020136055A (ru) | Kir3dl3 в качестве рецептора hhla2, анти-hhla2-антител и его использование | |
| JP2019523651A5 (enExample) | ||
| Gupta et al. | Development of an EGFRvIII specific recombinant antibody | |
| CN112513094A (zh) | 结合人her2的抗体、其制备方法和用途 | |
| JP2018520668A5 (enExample) | ||
| JP2012505659A5 (enExample) | ||
| JP2018535649A5 (enExample) | ||
| WO2022152185A1 (zh) | 靶向cd5的全人源抗体 | |
| RU2016129166A (ru) | Антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой терапии | |
| JPWO2022256563A5 (enExample) | ||
| JP2008538182A5 (enExample) | ||
| RU2017123022A (ru) | Гуманизованные антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой тарапии | |
| CN105504060A (zh) | 一种抗胃癌细胞表面功能性表达的足萼样蛋白前体亚型2的单克隆抗体及其制备方法和用途 | |
| JPWO2019169212A5 (enExample) | ||
| JPWO2019217145A5 (enExample) | ||
| WO2023159187A3 (en) | Anti-sars-cov2 spike (s) antibodies and uses thereof | |
| JP2020515286A5 (enExample) | ||
| JP2009507471A5 (enExample) |